Login Register Cart 0
Review Article

分泌簇蛋白是一种新型的抑制肝癌生长的分子靶向治疗方法

卷 27, 期 20, 2020

页: [3290 - 3301] 页: 12

弟呕挨: 10.2174/0929867326666190624161158

价格: $65

摘要

背景: 分泌簇蛋白(sCLU)在肝细胞癌(HCC)细胞增殖、耐多药(MDR)、转移等过程中发挥重要作用，但其靶向作用及确切机制尚不清楚。本文综述了近年来巩膜靶向治疗HCC分子靶向治疗的一些新进展。 方法: 利用PubMed和文献数据库系统回顾了已发表的关于sCLU和HCC的英文文献。检索有关sCLU和HCC在研究中的一些有价值的进展，检索相关文献，关键词:HCC、诊断、MDR、分子靶向治疗等。 结果: HCC组织中sCLU阳性率在mRNA或蛋白水平上明显高于周围组织，且随肿瘤分期逐渐升高(P<0.05)。此外，sCLU的异常水平与分化程度差有关，被认为是HCC诊断或患者独立预后的有用指标。肝sCLU可以沉默在mRNA水平由特定sCLU-shRNA或OGX- 011抑制癌症细胞增殖与细胞凋亡的增加,细胞周期阻滞,逆转MDR,改变细胞的迁移或入侵行为,并减少GSK-3β或一种蛋白激酶磷酸化体外,以及重要的抑制异种移植增长显示β-catenin, p-GSK3β,cyclinD1体内表达。 结论: 肝分泌簇蛋白（sCLU）异常表达不仅是一种新的诊断标志物，而且是抑制肝细胞癌生长的一种新的有前景的靶点。

关键词: 肝癌细胞 (HCC)

« Previous Next »
[1]
Bruix, J.; Reig, M.; Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150(4), 835-853.
[http://dx.doi.org/10.1053/j.gastro.2015.12.041] [PMID: 26795574]
[2]
Reig, M.; da Fonseca, L.G.; Faivre, S. New trials and results in systemic treatment of HCC. J. Hepatol., 2018, 69(2), 525-533.
[http://dx.doi.org/10.1016/j.jhep.2018.03.028] [PMID: 29653122]
[3]
Chen, J.G.; Zhu, J.; Zhang, Y.H.; Zhang, Y.X.; Yao, D.F.; Chen, Y.S.; Lu, J.H.; Ding, L.L.; Chen, H.Z.; Zhu, C.Y.; Yang, L.P.; Zhu, Y.R.; Qiang, F.L. Cancer survival in Qidong between 1972 and 2011: A population-based analysis. Mol. Clin. Oncol., 2017, 6(6), 944-954.
[http://dx.doi.org/10.3892/mco.2017.1234] [PMID: 28588795]
[4]
da Motta Girardi, D.; Correa, T.S.; Crosara Teixeira, M.; Dos Santos Fernandes, G. Hepatocellular carcinoma: review of targeted and immune therapies. J. Gastrointest. Cancer, 2018, 49(3), 227-236.
[http://dx.doi.org/10.1007/s12029-018-0121-4] [PMID: 29806062]
[5]
Raoul, J.L.; Kudo, M.; Finn, R.S.; Edeline, J.; Reig, M.; Galle, P.R. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat. Rev., 2018, 68(1), 16-24.
[http://dx.doi.org/10.1016/j.ctrv.2018.05.006] [PMID: 29783126]
[6]
Xie, M.; Yang, Z.; Liu, Y.; Zheng, M. The role of HBV-induced autophagy in HBV replication and HBV related-HCC. Life Sci., 2018, 205(1), 107-112.
[http://dx.doi.org/10.1016/j.lfs.2018.04.051] [PMID: 29709654]
[7]
Budzinska, M.A.; Shackel, N.A.; Urban, S.; Tu, T. Cellular genomic sites of hepatitis B virus DNA integration. Genes (Basel), 2018, 9(7) E365
[http://dx.doi.org/10.3390/genes9070365] [PMID: 30037029]
[8]
Nuño Solinís, R.; Arratibel Ugarte, P.; Rojo, A.; Sanchez Gonzalez, Y. Value of treating all stages of chronic hepatitis C: acomprehensive review of clinical and economic evidence. Infect. Dis. Ther., 2016, 5(4), 491-508.
[http://dx.doi.org/10.1007/s40121-016-0134-x] [PMID: 27783223]
[9]
Bang, C.S.; Song, I.H. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol., 2017, 17(1), 46-65.
[http://dx.doi.org/10.1186/s12876-017-0606-9] [PMID: 28376711]
[10]
El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, 142(6), 1264-1273.e1.
[http://dx.doi.org/10.1053/j.gastro.2011.12.061] [PMID: 22537432]
[11]
Bellentani, S. The epidemiology of non-alcoholic fatty liver disease. Liver Int., 2017, 37(Suppl. 1), 81-84.
[http://dx.doi.org/10.1111/liv.13299] [PMID: 28052624]
[12]
Kanda, T.; Matsuoka, S.; Yamazaki, M.; Shibata, T.; Nirei, K.; Takahashi, H.; Kaneko, T.; Fujisawa, M.; Higuchi, T.; Nakamura, H.; Matsumoto, N.; Yamagami, H.; Ogawa, M.; Imazu, H.; Kuroda, K.; Moriyama, M. Apoptosis and non-alcoholic fatty liver diseases. World J. Gastroenterol., 2018, 24(25), 2661-2672.
[http://dx.doi.org/10.3748/wjg.v24.i25.2661] [PMID: 29991872]
[13]
Liu, P.H.; Huo, T.I.; Miksad, R.A. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin. Liver Dis., 2018, 38(3), 242-251.
[http://dx.doi.org/10.1055/s-0038-1666805] [PMID: 30041276]
[14]
Jayachandran, M. An updated portrait of pathogenesis, molecular markers and signaling pathways of hepatocellular carcinoma. Curr. Pharm. Des., 2017, 23(16), 2356-2365.
[http://dx.doi.org/10.2174/1381612823666170329124852] [PMID: 28356044]
[15]
Kotha, S.; Neong, S.; Patel, K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev. Mol. Diagn., 2018, 18(8), 713-722.
[http://dx.doi.org/10.1080/14737159.2018.1496020] [PMID: 30019978]
[16]
Katoh, M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int. J. Mol. Med., 2018, 42(2), 713-725.
[http://dx.doi.org/10.3892/ijmm.2018.3689] [PMID: 29786110]
[17]
Juárez-Hernández, E.; Motola-Kuba, D.; Chávez-Tapia, N.C.; Uribe, M.; Barbero Becerra, V. Biomarkers in hepatocellular carcinoma: an overview. Expert Rev. Gastroenterol. Hepatol., 2017, 11(6), 549-558.
[http://dx.doi.org/10.1080/17474124.2017.1311785] [PMID: 28347162]
[18]
Eso, Y.; Marusawa, H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol. Res., 2018, 48(8), 597-607.
[http://dx.doi.org/10.1111/hepr.13181] [PMID: 29689631]
[19]
Novinec, M.; Lenarčič, B.; Baici, A. Clusterin is a specific stabilizer and liberator of extracellular cathepsin K. FEBS Lett., 2012, 586(7), 1062-1066.
[http://dx.doi.org/10.1016/j.febslet.2012.03.004] [PMID: 22569264]
[20]
Trougakos, I.P.; Djeu, J.Y.; Gonos, E.S.; Boothman, D.A. Advances and challenges in basic and translational research on clusterin. Cancer Res., 2009, 69(2), 403-406.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2912] [PMID: 19147550]
[21]
Goetz, E.M.; Shankar, B.; Zou, Y.; Morales, J.C.; Luo, X.; Araki, S.; Bachoo, R.; Mayo, L.D.; Boothman, D.A. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene, 2011, 30(35), 3745-3754.
[http://dx.doi.org/10.1038/onc.2011.92] [PMID: 21460853]
[22]
Wang, X.; Luo, L.; Dong, D.; Yu, Q.; Zhao, K. Clusterin plays an important role in clear renal cell cancer metastasis. Urol. Int., 2014, 92(1), 95-103.
[http://dx.doi.org/10.1159/000351923] [PMID: 24008723]
[23]
Zhang, H.; Kim, J.K.; Edwards, C.A.; Xu, Z.; Taichman, R.; Wang, C.Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol., 2005, 7(9), 909-915.
[http://dx.doi.org/10.1038/ncb1291] [PMID: 16113678]
[24]
Bertuzzi, M.; Marelli, C.; Bagnati, R.; Colombi, A.; Fanelli, R.; Saieva, C.; Ceroti, M.; Bendinelli, B.; Caini, S.; Airoldi, L.; Palli, D. Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study. BMC Cancer, 2015, 15(1), 56-67.
[http://dx.doi.org/10.1186/s12885-015-1058-7] [PMID: 25884309]
[25]
Xiu, P.; Dong, X.F.; Li, X.P.; Li, J. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J. Gastroenterol., 2015, 21(27), 8262-8270.
[http://dx.doi.org/10.3748/wjg.v21.i27.8262] [PMID: 26217078]
[26]
Wang, C.; Jiang, K.; Kang, X.; Gao, D.; Sun, C.; Li, Y.; Sun, L.; Zhang, S.; Liu, X.; Wu, W.; Yang, P.; Guo, K.; Liu, Y. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis. Int. J. Biochem. Cell Biol., 2012, 44(12), 2308-2320.
[http://dx.doi.org/10.1016/j.biocel.2012.09.012] [PMID: 23010347]
[27]
Zheng, W.J.; Sai, W.L.; Yao, M.; Cai, Y.; Pan, L.H.; Gu, J.J.; Wu, W.; Yao, D.F. [Down-regulated clusterin expression enhances sensitivity of hepatoma cells to anti-cancer drugs]. Chinese J. Hepatol., 2015, 23(11), 844-848.
[PMID: 26743245]
[28]
Lau, S.H.; Sham, J.S.; Xie, D.; Tzang, C.H.; Tang, D.; Ma, N.; Hu, L.; Wang, Y.; Wen, J.M.; Xiao, G.; Zhang, W.M.; Lau, G.K.; Yang, M.; Guan, X.Y. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene, 2006, 25(8), 1242-1250.
[http://dx.doi.org/10.1038/sj.onc.1209141] [PMID: 16247463]
[29]
Wang, C.; Jin, G.; Jin, H.; Wang, N.; Luo, Q.; Zhang, Y.; Gao, D.; Jiang, K.; Gu, D.; Shen, Q.; Huo, X.; Hu, F.; Ge, T.; Zhao, F.; Chu, W.; Shu, H.; Yao, M.; Cong, W.; Qin, W. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma. Oncotarget, 2015, 6(5), 2903-2916.
[http://dx.doi.org/10.18632/oncotarget.3093] [PMID: 25609201]
[30]
Luo, X.; Suzuki, M.; Ghandhi, S.A.; Amundson, S.A.; Boothman, D.A. ATM regulates insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) expression that protects cells against senescence. PLoS One, 2014, 9(6)e99983
[http://dx.doi.org/10.1371/journal.pone.0099983] [PMID: 24937130]
[31]
Wang, L.; Yao, M.; Dong, Z.; Zhang, Y.; Yao, D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol., 2014, 35(1), 9-20.
[http://dx.doi.org/10.1007/s13277-013-1141-0] [PMID: 24006223]
[32]
Yao, M.; Wang, L.; Fang, M.; Zheng, W.; Dong, Z.; Yao, D. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. Biosci. Trends, 2016, 10(5), 337-343.
[http://dx.doi.org/10.5582/bst.2016.01176] [PMID: 27795482]
[33]
Ma, H.; Sun, X.; Chen, L.; Cheng, W.; Han, X.X.; Zhao, B.; He, C. Multiplex immunochips for high-accuracy detection of AFP-L3% based on surface-enhanced raman scattering: implications for early liver cancer diagnosis. Anal. Chem., 2017, 89(17), 8877-8883.
[http://dx.doi.org/10.1021/acs.analchem.7b01349] [PMID: 28770990]
[34]
Pan, L.; Yao, M.; Zheng, W.; Gu, J.; Yang, X.; Qiu, L.; Cai, Y.; Wu, W.; Yao, D. Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. Tumour Biol., 2016, 37(4), 5561-5568.
[http://dx.doi.org/10.1007/s13277-015-4413-z] [PMID: 26577850]
[35]
Yao, M; Fang, M; Zheng, WJ DF Oncogenic Wnt3a: A promising specific biomarker in hepatocellular carcinoma. Hepat Res, 2018, 4(30)
[36]
Zheng, W.; Yao, M.; Sai, W.; Qian, Q.; Pan, L.; Qiu, L.; Huang, J.; Wu, W.; Yao, D. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. Tumour Biol., 2016, 37(1), 999-1008.
[http://dx.doi.org/10.1007/s13277-015-3875-3] [PMID: 26264614]
[37]
Yao, M.; Fang, M.; Zheng, W.; Dong, Z.; Yao, D. Role of secretory clusterin in hepatocarcinogenesis. Transl. Gastroenterol. Hepatol., 2018, 3, 48.
[http://dx.doi.org/10.21037/tgh.2018.07.13] [PMID: 30221206]
[38]
Ming, X.; Bao, C.; Hong, T.; Yang, Y.; Chen, X.; Jung, Y.S.; Qian, Y. Clusterin, a novel DEC1 target, modulates DNA damage-mediated cell death. Mol. Cancer Res., 2018, 16(11), 1641-1651.
[http://dx.doi.org/10.1158/1541-7786.MCR-18-0070] [PMID: 30002194]
[39]
Jin, R.; Chen, X.; Han, D.; Luo, X.; Li, H. Clusterin modulates transdifferentiation of non-small-cell lung cancer. BMC Cancer, 2017, 17(1), 661.
[http://dx.doi.org/10.1186/s12885-017-3649-y] [PMID: 28954633]
[40]
Kim, Y.S.; Jin, H.O.; Hong, S.E.; Song, J.Y.; Hwang, C.S.; Park, I.C. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin. Biochem. Biophys. Res. Commun., 2018, 495(2), 2004-2009.
[http://dx.doi.org/10.1016/j.bbrc.2017.12.077] [PMID: 29253572]
[41]
Pucci, S.; Polidoro, C.; Joubert, A.; Mastrangeli, F.; Tolu, B.; Benassi, M.; Fiaschetti, V.; Greco, L.; Miceli, R.; Floris, R.; Novelli, G.; Orlandi, A.; Santoni, R. Ku70, Ku80, and sClusterin: a cluster of predicting factors for response to neoadjuvant chemo-radiation therapy in patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2017, 97(2), 381-388.
[http://dx.doi.org/10.1016/j.ijrobp.2016.10.018] [PMID: 28068245]
[42]
Wang, C.; Jiang, K.; Gao, D.; Kang, X.; Sun, C.; Zhang, Q.; Li, Y.; Sun, L.; Zhang, S.; Guo, K.; Liu, Y. Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78. PLoS One, 2013, 8(2)e55981
[http://dx.doi.org/10.1371/journal.pone.0055981] [PMID: 23457489]
[43]
Zoubeidi, A.; Chi, K.; Gleave, M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin. Cancer Res., 2010, 16(4), 1088-1093.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2917] [PMID: 20145158]
[44]
Shim, Y.J.; Kang, B.H.; Jeon, H.S.; Park, I.S.; Lee, K.U.; Lee, I.K.; Park, G.H.; Lee, K.M.; Schedin, P.; Min, B.H. Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages. J. Leukoc. Biol., 2011, 90(4), 761-769.
[http://dx.doi.org/10.1189/jlb.0311110] [PMID: 21742938]
[45]
Ammar, H.; Closset, J.L. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem., 2008, 283(19), 12851-12861.
[http://dx.doi.org/10.1074/jbc.M800403200] [PMID: 18321852]
[46]
Chen, X.; Jiang, Y.; Huang, Z.; Li, D.; Chen, X.; Cao, M.; Meng, Q.; Pang, H.; Sun, L.; Zhao, Y.; Cai, L. miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci. Rep., 2016, 6, 19455.
[http://dx.doi.org/10.1038/srep19455] [PMID: 26781643]
[47]
Zhang, Q.; Ray, K.; Acland, G.M.; Czarnecki, J.M.; Aguirre, G.D. Molecular cloning, characterization and expression of a novel retinal clusterin-like protein cDNA. Gene, 2000, 243(1-2), 151-160.
[http://dx.doi.org/10.1016/S0378-1119(99)00542-9] [PMID: 10675623]
[48]
García-Aranda, M.; Téllez, T.; Muñoz, M.; Redondo, M. Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. Anticancer Drugs, 2017, 28(7), 702-716.
[http://dx.doi.org/10.1097/CAD.0000000000000507] [PMID: 28471806]
[49]
Wilson, M.R.; Zoubeidi, A. Clusterin as a therapeutic target. Expert Opin. Ther. Targets, 2017, 21(2), 201-213.
[http://dx.doi.org/10.1080/14728222.2017.1267142] [PMID: 27978767]
[50]
Sheng, X.; Huang, T.; Qin, J.; Yang, L.; Sa, Z.Q.; Li, Q. Identification of the differential expression profiles of serum and tissue proteins during rat hepatocarcinogenesis. Technol. Cancer Res. Treat., 2018, 171533034618756785
[http://dx.doi.org/10.1177/1533034618756785] [PMID: 29478368]
[51]
Zhou, J.; Donatelli, S.S.; Gilvary, D.L.; Tejera, M.M.; Eksioglu, E.A.; Chen, X.; Coppola, D.; Wei, S.; Djeu, J.Y. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Sci. Rep., 2016, 6, 29521.
[http://dx.doi.org/10.1038/srep29521] [PMID: 27405665]
[52]
Lee, J.Y.; Kim, H.J.; Rho, S.B.; Lee, S.H. eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells. Oncotarget, 2016, 7(14), 18541-18557.
[http://dx.doi.org/10.18632/oncotarget.8105] [PMID: 26988917]
[53]
Zhou, J.; Chen, X.; Gilvary, D.L.; Tejera, M.M.; Eksioglu, E.A.; Wei, S.; Djeu, J.Y. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci. Rep., 2015, 5, 15085.
[http://dx.doi.org/10.1038/srep15085] [PMID: 26469759]
[54]
Zhang, J.; Miao, C.; Xu, A.; Zhao, K.; Qin, Z.; Li, X.; Liang, C.; Hua, Y.; Chen, W.; Zhang, C.; Liu, Y.; Su, S.; Wang, Z.; Liu, B. Prognostic role of cecretory clusterin in multiple human malignant neoplasms: A meta-analysis of 26 immunohistochemistry studies. PLoS One, 2016, 11(8) e0161150
[http://dx.doi.org/10.1371/journal.pone.0161150] [PMID: 27532124]
[55]
Ehsani Ardakani, M.J.; Safaei, A.; Arefi Oskouie, A.; Haghparast, H.; Haghazali, M.; Mohaghegh Shalmani, H.; Peyvandi, H.; Naderi, N.; Zali, M.R. Evaluation of liver cirrhosis and hepatocellular carcinoma using Protein-Protein Interaction Networks. Gastroenterol. Hepatol. Bed Bench, 2016, 9(Suppl. 1), S14-S22.
[PMID: 28224023]
[56]
Rosemblit, N.; Chen, C.L. Regulators for the rat clusterin gene: DNA methylation and cis-acting regulatory elements. J. Mol. Endocrinol., 1994, 13(1), 69-76.
[http://dx.doi.org/10.1677/jme.0.0130069] [PMID: 7999255]
[57]
Chen, R.X.; Song, H.Y.; Dong, Y.Y.; Hu, C.; Zheng, Q.D.; Xue, T.C.; Liu, X.H.; Zhang, Y.; Chen, J.; Ren, Z.G.; Liu, Y.K.; Cui, J.F. Dynamic expression patterns of differential proteins during early invasion of hepatocellular carcinoma. PLoS One, 2014, 9(3) e88543
[http://dx.doi.org/10.1371/journal.pone.0088543] [PMID: 24614035]
[58]
Kimura, A.; Sogawa, K.; Satoh, M.; Kodera, Y.; Yokosuka, O.; Tomonaga, T.; Nomura, F. The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma. Int. J. Proteomics, 2012, 2012 623190
[http://dx.doi.org/10.1155/2012/623190] [PMID: 22957256]
[59]
Malhi, H.; Kaufman, R.J. Endoplasmic reticulum stress in liver disease. J. Hepatol., 2011, 54(4), 795-809.
[http://dx.doi.org/10.1016/j.jhep.2010.11.005] [PMID: 21145844]
[60]
Wang, B.G.; Jiang, L.Y.; Xu, Q. Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis. Biosci. Rep., 2018, 38(5)pii BSR20180712
[http://dx.doi.org/10.1042/BSR20180712] [PMID: 29976775]
[61]
Kang, Y.K.; Hong, S.W.; Lee, H.; Kim, W.H. Overexpression of clusterin in human hepatocellular carcinoma. Hum. Pathol., 2004, 35(11), 1340-1346.
[http://dx.doi.org/10.1016/j.humpath.2004.07.021] [PMID: 15668890]
[62]
Zheng, W.; Yao, M.; Qian, Q.; Sai, W.; Qiu, L.; Yang, J.; Wu, W.; Dong, Z.; Yao, D. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget, 2016, 8(32), 52321-52332.
[PMID: 28881732]
[63]
Aigelsreiter, A.; Janig, E.; Sostaric, J.; Pichler, M.; Unterthor, D.; Halasz, J.; Lackner, C.; Zatloukal, K.; Denk, H. Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis. Histopathology, 2009, 54(5), 561-570.
[http://dx.doi.org/10.1111/j.1365-2559.2009.03258.x] [PMID: 19413638]
[64]
Lai, J.P.; Chen, Z.M.; Lok, T.; Chan, O.T.; Himmelfarb, E.; Zhai, Q.; Lin, F.; Wang, H.L. Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions. J. Clin. Pathol., 2014, 67(6), 464-469.
[http://dx.doi.org/10.1136/jclinpath-2013-201907] [PMID: 24407433]
[65]
Loison, F.; Debure, L.; Nizard, P.; le Goff, P.; Michel, D.; le Dréan, Y. Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem. J., 2006, 395(1), 223-231.
[http://dx.doi.org/10.1042/BJ20051190] [PMID: 16336210]
[66]
Zheng, W.; Yao, M.; Wu, M. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis. J. Transl. Med., 2020, 18(1), 81.https://www.ncbi.nlm.nih.gov/pubmed/320597412020
[http://dx.doi.org/10.1186/s12967-020-02262-7] [PMID: 32059741]
[67]
Wang, Y.; Liu, Y.H.; Mai, S.J.; He, L.J.; Liao, Y.J.; Deng, H.X.; Guan, X.Y.; Zeng, Y.X.; Kung, H.F.; Xie, D. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. J. Gastroenterol. Hepatol., 2010, 25(6), 1123-1128.
[http://dx.doi.org/10.1111/j.1440-1746.2009.06205.x] [PMID: 20594228]
[68]
Comunale, M.A.; Wang, M.; Rodemich-Betesh, L.; Hafner, J.; Lamontagne, A.; Klein, A.; Marrero, J.; Di Bisceglie, A.M.; Gish, R.; Block, T.; Mehta, A. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev., 2011, 20(6), 1222-1229.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-1047] [PMID: 21467232]
[69]
Nafee, A.M.; Pasha, H.F.; Abd El Aal, S.M.; Mostafa, N.A. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin. Biochem., 2012, 45(13-14), 1070-1074.
[http://dx.doi.org/10.1016/j.clinbiochem.2012.04.024] [PMID: 22580393]
[70]
Criswell, T.; Beman, M.; Araki, S.; Leskov, K.; Cataldo, E.; Mayo, L.D.; Boothman, D.A. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J. Biol. Chem., 2005, 280(14), 14212-14221.
[http://dx.doi.org/10.1074/jbc.M412569200] [PMID: 15689620]
[71]
Klokov, D.; Leskov, K.; Araki, S.; Zou, Y.; Goetz, E.M.; Luo, X.; Willson, D.; Boothman, D.A. Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect. Oncogene, 2013, 32(4), 479-490.
[http://dx.doi.org/10.1038/onc.2012.64] [PMID: 22391565]
[72]
Ceballos, M.P.; Rigalli, J.P.; Ceré, L.I.; Semeniuk, M.; Catania, V.A.; Ruiz, M.L. ABC transporters: Regulation and association with multidrug resistance in hepato- cellular carcinoma and colorectal carcinoma. Curr. Med. Chem., 2019, 26(7), 1224-1250.
[http://dx.doi.org/10.2174/0929867325666180105103637] [PMID: 29303075]
[73]
Shi, Y.; Yao, M.; Yao, D. [Recent advances in understanding reversion of multidrug resistance in hepatocellular carcinoma cells]. Zhonghua Gan Zang Bing Za Zhi, 2014, 22(9), 715-717.
[PMID: 25647850]
[74]
Gu, X.; Yao, M.; Wang, S.; Shi, Y.; Dong, Z.; Qiu, L.; Yao, D. [Inhibitory effects of intervention of the TNFa/NF-kappaB signaling pathway activation on hepatoma cell proliferation]. Zhonghua Gan Zang Bing Za Zhi, 2014, 22(6), 434-439.
[PMID: 25203707]
[75]
Poupon, R.; Fartoux, L.; Rosmorduc, O. [Therapeutic advances in hepatocellular carcinoma]. Bull. Acad Natl. Med., 2008, 192(1), 23-31.
[http://dx.doi.org/10.1016/S0001-4079(19)32864-X] [PMID: 18663979]
[76]
Yao, M.; Gu, X.; Wang, L.; Cai, Y.; Wu, W.; Shi, Y.; Dong, Z.; Yao, D. [Abnormal expression of circulating nuclear factor-κB in hepatocellular carcinoma and reversal of multidrug resistance through intervening its gene transcription]. Zhonghua Yi Xue Za Zhi, 2016, 96(10), 761-766.
[PMID: 27055634]
[77]
Ye, J.Z.; Yan, S.M.; Yuan, C.L.; Wu, H.N.; Zhang, J.Y.; Liu, Z.H.; Li, Y.Q.; Luo, X.L.; Lin, Y.; Liang, R. GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells. J. Cancer, 2018, 9(2), 415-423.
[http://dx.doi.org/10.7150/jca.19185] [PMID: 29344288]
[78]
Li, H.; Zhou, S.; Li, T.; Liu, Z.; Wu, J.; Zeng, G.; Liu, C.; Gong, J. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference. Hepatogastroenterology, 2012, 59(119), 2238-2242.
[PMID: 23435138]
[79]
Zheng, W.; Sai, W.; Yao, M.; Gu, H.; Yao, Y.; Qian, Q.; Yao, D. Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. Tumour Biol., 2015, 36(5), 3995-4003.
[http://dx.doi.org/10.1007/s13277-015-3043-9] [PMID: 25600802]
[80]
Xiu, P.; Xu, Z.; Liu, F.; Li, Z.; Li, T.; Zou, F.; Sun, X.; Li, J. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway. Dig. Dis. Sci., 2014, 59(8), 1798-1809.
[http://dx.doi.org/10.1007/s10620-014-3111-9] [PMID: 24671452]
[81]
Wang, X.; Zou, F.; Zhong, J.; Yue, L.; Wang, F.; Wei, H.; Yang, G.; Jin, T.; Dong, X.; Li, J.; Xiu, P. Secretory clusterin mediates oxaliplatin resistance via the Gadd45a/PI3K/ Akt signaling pathway in hepatocellular carcinoma. J. Cancer, 2018, 9(8), 1403-1413.
[http://dx.doi.org/10.7150/jca.23849] [PMID: 29721050]
[82]
Zhong, J.; Yu, X.; Dong, X.; Lu, H.; Zhou, W.; Li, L.; Li, Z.; Sun, P.; Shi, X. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals. Int. J. Mol. Med., 2018, 41(5), 2893-2900.
[http://dx.doi.org/10.3892/ijmm.2018.3463] [PMID: 29436591]
[83]
Xiu, P.; Dong, X.; Dong, X.; Xu, Z.; Zhu, H.; Liu, F.; Wei, Z.; Zhai, B.; Kanwar, J.R.; Jiang, H.; Li, J.; Sun, X. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci., 2013, 104(3), 375-382.
[http://dx.doi.org/10.1111/cas.12088] [PMID: 23279642]
[84]
Wang, Y.W.; Lin, K.T.; Chen, S.C.; Gu, D.L.; Chen, C.F.; Tu, P.H.; Jou, Y.S. Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma. Hepatology, 2013, 58(1), 239-250.
[http://dx.doi.org/10.1002/hep.26352] [PMID: 23460382]
[85]
Zhong, J.; Yu, X.; Dong, X.; Lu, H.; Zhou, W.; Li, L.; Li, Z.; Sun, P.; Shi, X. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells. Oncol. Lett., 2018, 15(5), 7191-7199.
[http://dx.doi.org/10.3892/ol.2018.8186] [PMID: 29731881]
[86]
Shiota, M.; Zardan, A.; Takeuchi, A.; Kumano, M.; Beraldi, E.; Naito, S.; Zoubeidi, A.; Gleave, M.E. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res., 2012, 72(20), 5261-5272.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-0254] [PMID: 22896337]
[87]
Koltai, T. Clusterin: a key player in cancer chemoresistance and its inhibition. OncoTargets Ther., 2014, 7(4), 447-456.
[http://dx.doi.org/10.2147/OTT.S58622] [PMID: 24672247]
[88]
Essabbani, A.; Garcia, L.; Zonetti, M.J.; Fisco, T.; Pucci, S.; Chiocchia, G. Exon-skipping strategy by ratio modulation between cytoprotective versus pro-apoptotic clusterin forms increased sensitivity of LNCaP to cell death. PLoS One, 2013, 8(2)e54920
[http://dx.doi.org/10.1371/journal.pone.0054920] [PMID: 23418433]
[89]
Chang, W.T.; Lu, S.N.; Rau, K.M.; Huang, C.S.; Lee, K.T. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. Kaohsiung J. Med. Sci., 2018, 34(7), 391-399.
[http://dx.doi.org/10.1016/j.kjms.2018.03.006] [PMID: 30063012]
[90]
Choi, B.; Kang, S.S.; Kang, S.W.; Min, B.H.; Lee, E.J.; Song, D.H.; Kim, S.M.; Song, Y.; Yoon, S.Y.; Chang, E.J. Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation. Biochem. Biophys. Res. Commun., 2014, 450(1), 105-109.
[http://dx.doi.org/10.1016/j.bbrc.2014.05.074] [PMID: 24866235]
[91]
Fu, Y.; Lai, Y.; Liu, J.; Liu, X.; You, Z.; Yang, G. Lentivirus-mediated shRNA interference of clusterin blocks proliferation, motility, invasion and cell cycle in the ovarian cancer cells. J. Ovarian Res., 2015, 8(1), 59-67.
[http://dx.doi.org/10.1186/s13048-015-0173-z] [PMID: 26293319]
[92]
Huang, H.; Wang, L.; Li, M.; Wang, X.; Zhang, L. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells. World J. Surg. Oncol., 2014, 12(2), 255-264.
[http://dx.doi.org/10.1186/1477-7819-12-255] [PMID: 25106434]
[93]
Choi, S.H.; Park, J.Y. Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. Cancer Cell Int., 2017, 17(1), 3-11.
[http://dx.doi.org/10.1186/s12935-016-0374-6] [PMID: 28053598]
[94]
Amicone, L.; Marchetti, A. Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Transl. Gastroenterol. Hepatol., 2018, 3(1), 24.
[http://dx.doi.org/10.21037/tgh.2018.04.05] [PMID: 29971255]
[95]
Llovet, J.M.; Montal, R.; Sia, D.; Finn, R.S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol., 2018, 15(10), 599-616.
[http://dx.doi.org/10.1038/s41571-018-0073-4] [PMID: 30061739]
[96]
Wang, M.; Yu, F.; Li, P. Circular RNAs: characteristics, function and clinical significance in hepatocellular carcinoma. Cancers (Basel), 2018, 10(8) E258
[http://dx.doi.org/10.3390/cancers10080258] [PMID: 30072625]
[97]
Lamoureux, F.; Thomas, C.; Yin, M.J.; Kuruma, H.; Beraldi, E.; Fazli, L.; Zoubeidi, A.; Gleave, M.E. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res., 2011, 71(17), 5838-5849.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-0994] [PMID: 21737488]
[98]
Saad, F.; Hotte, S.; North, S.; Eigl, B.; Chi, K.; Czaykowski, P.; Wood, L.; Pollak, M.; Berry, S.; Lattouf, J.B.; Mukherjee, S.D.; Gleave, M.; Winquist, E. Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res., 2011, 17(17), 5765-5773.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-0859] [PMID: 21788353]
[99]
Chen, D.; Wang, Y.; Zhang, K.; Jiao, X.; Yan, B.; Liang, J. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin. Int. J. Mol. Sci., 2012, 13(8), 10594-10607.
[http://dx.doi.org/10.3390/ijms130810594] [PMID: 22949882]
[100]
Burkhart, R.A.; Ronnekleiv-Kelly, S.M.; Pawlik, T.M. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg. Oncol., 2017, 26(2), 138-145.
[http://dx.doi.org/10.1016/j.suronc.2017.01.009] [PMID: 28577719]
[101]
Mukaida, N.; Nakamoto, Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J. Gastroenterol., 2018, 24(17), 1839-1858.
[http://dx.doi.org/10.3748/wjg.v24.i17.1839] [PMID: 29740200]
[102]
Nishida, N.; Kudo, M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol. Res., 2018, 48(8), 622-634.
[http://dx.doi.org/10.1111/hepr.13191] [PMID: 29734514]
[103]
Zhang. J.; Wu. M.; Xu. Y.; Song. Q.; Zheng. W. Secretory clusterin: A promising target for chemo-resistance of hepatocellular carcinoma. Mini. Rev. Med. Chem., https://www.ncbi.nlm.nih.gov/ pubmed/322284222020
[http://dx.doi.org/10.2174/1389557520666200331072122] [PMID: 32228422]
[104]
Yao, M.; Wang, L.; Qiu, L.; Qian, Q.; Yao, D. Encouraging microRNA-based therapeutic strategies for hepatocellular carcinoma. Anticancer. Agents Med. Chem., 2015, 15(4), 453-460.
[http://dx.doi.org/10.2174/1871520615666141216150135] [PMID: 25511513]
[105]
Sheng, J.; Qin, H.; Zhang, K.; Li, B.; Zhang, X. Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma. Am. J. Cancer Res., 2018, 8(3), 354-365.
[PMID: 29636994]
[106]
Pan, L.H.; Yao, M.; Cai, Y.; Gu, J.J.; Yang, X.L.; Wang, L.; Yao, D.F. Oncogenic Wnt3a expression as an estimable prognostic marker for hepatocellular carcinoma. World J. Gastroenterol., 2016, 22(14), 3829-3836.
[http://dx.doi.org/10.3748/wjg.v22.i14.3829] [PMID: 27076768]
[107]
Waidmann, O. Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin. Biol. Ther., 2018, 18(8), 905-910.
[http://dx.doi.org/10.1080/14712598.2018.1499722] [PMID: 29995439]
[108]
Liu, P.; Chen, L.; Zhang, H. Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell-based immunotherapy. J. Immunol. Res., 2018, 2018 1206737
[http://dx.doi.org/10.1155/2018/1206737] [PMID: 30255103]

Rights & Permissions Print Cite
Article Metrics
28
2
© 2024 Bentham Science Publishers | Privacy Policy